Gerald Batist
#153,451
Most Influential Person Now
Gerald Batist's AcademicInfluence.com Rankings
Gerald Batistphilosophy Degrees
Philosophy
#8576
World Rank
#11984
Historical Rank
Logic
#5609
World Rank
#7020
Historical Rank
Gerald Batistbiology Degrees
Biology
#11645
World Rank
#15056
Historical Rank
Biochemistry
#1943
World Rank
#2084
Historical Rank
Download Badge
Philosophy Biology
Gerald Batist's Degrees
- Doctorate Medicine McGill University
- PhD Biochemistry McGill University
Why Is Gerald Batist Influential?
(Suggest an Edit or Addition)Gerald Batist's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (2020) (1264)
- Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. (2001) (1136)
- Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. (1986) (762)
- Use of statins and the risk of death in patients with prostate cancer. (2014) (656)
- Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions (2016) (647)
- Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. (2001) (636)
- Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. (1985) (585)
- Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma (2002) (482)
- Transcriptional Regulation of NF-E2 p45-related Factor (NRF2) Expression by the Aryl Hydrocarbon Receptor-Xenobiotic Response Element Signaling Pathway (2005) (442)
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (294)
- Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. (1986) (290)
- Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis (2000) (234)
- Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells (2002) (229)
- Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. (1987) (222)
- Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. (2003) (189)
- Systemic cancer therapy: achievements and challenges that lie ahead (2013) (186)
- Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors (2009) (183)
- Deficiency of connexin43 gap junctions is an independent marker for breast tumors. (1999) (177)
- Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial (2021) (154)
- Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. (2011) (152)
- Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. (1998) (130)
- Gap junctions and connexins as therapeutic targets in cancer (2010) (128)
- Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy (2002) (122)
- Differences in phosphate metabolite levels in drug-sensitive and -resistant human breast cancer cell lines determined by 31P magnetic resonance spectroscopy. (1986) (111)
- Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. (1987) (107)
- Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. (1999) (105)
- The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity action. (2006) (105)
- Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. (2011) (104)
- Whey proteins in cancer prevention. (1991) (102)
- Immunoenhancing property of dietary whey protein in mice: role of glutathione. (1989) (102)
- Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer (2003) (100)
- E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells (2004) (99)
- Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. (2002) (98)
- Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy (2009) (98)
- Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis (2006) (94)
- A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. (2002) (89)
- The influence of dietary whey protein on tissue glutathione and the diseases of aging. (1989) (87)
- Biopsies: next-generation biospecimens for tailoring therapy (2013) (86)
- The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer (2019) (85)
- Glutathione and glutathione analogues; therapeutic potentials. (2013) (85)
- Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. (1999) (84)
- A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers (2017) (81)
- Connexin43 pseudogene is expressed in tumor cells and inhibits growth (2004) (81)
- Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. (1999) (73)
- Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. (2015) (72)
- Selenium-induced cytotoxicity of human leukemia cells: interaction with reduced glutathione. (1986) (71)
- Pulmonary toxicity of antineoplastic drugs. (1981) (70)
- Small-cell carcinoma of lung: reinduction therapy after late relapse. (1983) (69)
- Medication Problems in Older, Newly Diagnosed Cancer Patients in Canada: How Common are They? (2009) (69)
- Overexpression of Cytochrome P-450 Isoforms Involved in Aflatoxin B1 Bioactivation in Human Liver with Cirrhosis and Hepatitis (1996) (68)
- Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. (1995) (67)
- Altered amino acid kinetics in rats with progressive tumor growth. (1982) (63)
- Potential for selective modulation of glutathione in cancer chemotherapy. (1998) (63)
- In the end what matters most? A review of clinical endpoints in advanced breast cancer. (2011) (61)
- Unexpected induction of the human connexin 43 promoter by the ras signaling pathway is mediated by a novel putative promoter sequence. (2003) (60)
- The Role of Connexin-Mediated Cell–Cell Communication in Breast Cancer Metastasis (2001) (60)
- A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer (2005) (60)
- A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. (2003) (59)
- A novel missense mutation in the gamma-glutamylcysteine synthetase catalytic subunit gene causes both decreased enzymatic activity and glutathione production. (2003) (58)
- Evaluation of denaturing high‐performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall‐cell lung cancer (2006) (57)
- The impact of a multimedia informational intervention on psychosocial adjustment among individuals with newly diagnosed breast or prostate cancer: a feasibility study. (2010) (55)
- High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study (2020) (54)
- Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies (2010) (54)
- Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. (2003) (54)
- Usefulness of Frailty Markers in the Assessment of the Health and Functional Status of Older Cancer Patients Referred for Chemotherapy: A Pilot Study (2008) (54)
- The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. (2020) (53)
- Cyclic-AMP induction of gap junctional intercellular communication increases bystander effect in suicide gene therapy. (1999) (52)
- Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry (2018) (51)
- Upregulation of gap junctional intercellular communication and connexin 43 expression by cyclic-AMP and all-trans-retinoic acid is associated with glutathione depletion and chemosensitivity in neuroblastoma cells (2000) (51)
- The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathways (2010) (50)
- Targeted and Untargeted Proteomics Approaches in Biomarker Development (2019) (50)
- Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistance. (1995) (49)
- Nrf2 Transcription Factor Can Directly Regulate mTOR (2016) (48)
- Glutathione S-transferase in chemotherapy resistance and in carcinogenesis. (1992) (48)
- Retroviral expression of the hepatitis B virus x gene promotes liver cell susceptibility to carcinogen-induced site specific mutagenesis. (2000) (48)
- The biology behind prognostic factors of cutaneous melanoma (2010) (47)
- The fall rate of older community-dwelling cancer patients (2013) (46)
- Does frailty predict hospitalization, emergency department visits, and visits to the general practitioner in older newly-diagnosed cancer patients? Results of a prospective pilot study. (2010) (45)
- Co-prevalence of Epstein–Barr virus and high-risk human papillomaviruses in Syrian women with breast cancer (2016) (45)
- Expression of a rat glutathione-S-transferase complementary DNA in rat mammary carcinoma cells: impact upon alkylator-induced toxicity. (1993) (45)
- Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line. (1989) (45)
- In vivo and in vitro mechanisms of drug resistance in a rat mammary carcinoma model. (1991) (43)
- Implications for therapy of drug-metabolizing enzymes in human colon cancer. (1989) (43)
- Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells. (2014) (43)
- A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group (2005) (42)
- Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR (2020) (40)
- Difficulties in decision making regarding chemotherapy for older cancer patients: A census of cancer physicians. (2011) (39)
- Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target (2009) (39)
- Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers alkylating drug resistance in NIH 3T3 mouse fibroblasts. (1994) (39)
- Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. (1986) (38)
- Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cells in vitro. (1986) (38)
- Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells (2004) (38)
- Comparing Clinical Characteristics and Outcomes of Young‐onset and Late‐onset Colorectal Cancer: An International Collaborative Study (2017) (38)
- A histone deacetylation‐dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells (2006) (38)
- Characteristics of older newly diagnosed cancer patients refusing cancer treatments (2010) (38)
- Radiation-induced damage to DNA in drug- and radiation-resistant sublines of a human breast cancer cell line. (1992) (37)
- Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues. (2003) (37)
- Syntheses and potential anti-prostate cancer activities of ionone-based chalcones. (2009) (36)
- Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents. (1995) (35)
- Transforming Growth Factor β1 Promotes Spontaneous Transformation of Cultured Rat Liver Epithelial Cells (1994) (34)
- A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880). (1985) (34)
- Role of HSP90 in mediating cross-talk between the estrogen receptor and the Ah receptor signal transduction pathways. (1999) (34)
- Barriers and facilitators of adherence to medical advice on skin self-examination during melanoma follow-up care (2013) (34)
- Modulation of Glutathione S-Transferase Alpha by Hepatitis B Virus and the Chemopreventive Drug Oltipraz* (2000) (34)
- Oltipraz is a bifunctional inducer activating both phase I and phase II drug-metabolizing enzymes via the xenobiotic responsive element. (2003) (33)
- Eradication of hepatic metastases of carcinoma H-59 by combination chemoimmunotherapy with liposomal muramyl tripeptide, 5-fluorouracil, and leucovorin. (1992) (33)
- Radiation response of drug-resistant variants of a human breast cancer cell line. (1989) (32)
- Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine (2013) (32)
- Glutathione analogues in cancer treatment (2004) (32)
- Glutathione depletion in human and in rat multi-drug resistant breast cancer cell lines. (1991) (31)
- Low antithrombin III in morbid obesity: return to normal with weight reduction. (1983) (31)
- Cardiac safety of liposomal anthracyclines (2007) (30)
- Benefits, issues, and recommendations for personalized medicine in oncology in Canada. (2013) (30)
- In vivo selective modulation of tissue glutathione in a rat mammary carcinoma model. (1995) (30)
- Clinical experience of cancer specialists and geriatricians involved in cancer care of older patients: A qualitative study. (2010) (30)
- Aorticopulmonary paraganglioma and gastric leiomyoblastoma in a young woman. (1981) (30)
- Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate. (1996) (29)
- Incidence of Epstein–Barr virus in Syrian women with breast cancer: A tissue microarray study (2015) (29)
- Imiquimod in the treatment of breast cancer skin metastasis. (2014) (28)
- Allele‐specific PCR analysis of p53 codon 249 AGT transversion in liver tissues from patients with viral hepatitis (1996) (28)
- Usefulness of frailty markers in the assessment of the health and functional status of older cancer patients referred for chemotherapy: a pilot study. (2006) (28)
- Design and synthesis of analogs of vitamin E: antiproliferative activity against human breast adenocarcinoma cells. (1998) (28)
- The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases (2015) (28)
- A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens. (2019) (28)
- Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. (2020) (28)
- Participation of older newly-diagnosed cancer patients in an observational prospective pilot study: an example of recruitment and retention (2009) (28)
- A multicenter, phase II study of CPX-1 liposome injection in patients (pts) with advanced colorectal cancer (CRC) (2008) (27)
- Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer. (2016) (27)
- Potential Medication Problems in Older Newly Diagnosed Cancer Patients in Canada during Cancer Treatment (2010) (27)
- Co-Incidence of Epstein–Barr Virus and High-Risk Human Papillomaviruses in Cervical Cancer of Syrian Women (2018) (26)
- Relation of glutathione S-transferase α and μ isoforms to response to therapy in human breast cancer (1997) (26)
- Æ-941 (Neovastat®): a novel multifunctional antiangiogenic compound (2001) (26)
- Radiation response of drug-resistant variants of a human breast cancer cell line: the effect of glutathione depletion. (1990) (25)
- Regulation of the gap junction connexin 43 gene by androgens in the prostate. (2001) (24)
- Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors. (2017) (24)
- Quality of life during the course of cancer treatment in older newly diagnosed patients. Results of a prospective pilot study. (2011) (24)
- Lung cancer care trajectory at a Canadian centre: an evaluation of how wait times affect clinical outcomes. (2017) (24)
- Response to ischemia-reperfusion injury in hypertrophic heart. Role of free-radical metabolic pathways. (1989) (23)
- Genetic alteration of chromosome 8 is a common feature of human mammary epithelial cell lines transformed in vitro with benzo[a]pyrene. (2001) (23)
- Cardiac and red blood cell glutathione peroxidase: results of a prospective randomized trial in patients on total parenteral nutrition. (1985) (23)
- Identification and Characterization of Novel Nrf2 Inducers Designed to Target the Intervening Region of Keap1 (2010) (22)
- A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer (2015) (22)
- Co-presence of human papillomaviruses and Epstein–Barr virus is linked with advanced tumor stage: a tissue microarray study in head and neck cancer patients (2020) (22)
- Biopsies: next-generation biospecimens for tailoring therapy (2013) (22)
- Lack of cross-resistance to a new cytotoxic arylchloroethyl urea in various drug-resistant tumor cells (2004) (22)
- Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors. (2005) (21)
- Characterization of 5-oxo-L-prolinase in normal and tumor tissues of humans and rats: a potential new target for biochemical modulation of glutathione. (1998) (21)
- Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. (2009) (21)
- Modulation of glutathione by a cysteine pro-drug enhances in vivo tumor response. (1996) (20)
- The biology of melanoma prognostic factors. (2010) (20)
- Epidermal growth factor receptor mutations detected by denaturing high‐performance liquid chromatography in nonsmall cell lung cancer (2010) (20)
- Structure-Based Identification of Novel Human γ-Glutamylcysteine Synthetase Inhibitors (2007) (20)
- An examination of how different mutations at arginine 855 of the androgen receptor result in different androgen insensitivity phenotypes. (2004) (20)
- Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. (1998) (20)
- Toward Implementing Patient Flow in a Cancer Treatment Center to Reduce Patient Waiting Time and Improve Efficiency. (2017) (19)
- The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience (2017) (19)
- A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies. (2013) (19)
- Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits (2017) (19)
- Efficacy and toxicity of ifosfamide stereoisomers in an in vivo rat mammary carcinoma model. (1994) (19)
- Effects of low-dose warfarin on antithrombin III levels in morbidly obese patients. (1983) (19)
- Resistance to Cancer Treatment: The Role of Somatic Genetic Events and the Challenges for Targeted Therapies (2011) (19)
- A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance (2020) (19)
- Magnetotactic bacteria penetration into multicellular tumor spheroids for targeted therapy (2010) (19)
- Enzymatic defense against radiation damage in mice. Effect of selenium and vitamin E depletion. (1986) (18)
- A cell-based system to identify and characterize the molecular mechanism of drug-metabolizing enzyme (DME) modulators. (2004) (18)
- Synthesis and cytotoxic evaluation of some styryl ketones and related compounds (1995) (18)
- Deficiency of Connexin 43 Gap Junctions Is an Independent Marker for Breast Tumors 1 (1999) (18)
- Phenotypic expression in spontaneously transformed cultured rat liver epithelial cells. (1990) (17)
- Quantitation of the diastereoisomers of L-buthionine-(R,S)-sulfoximine in human plasma: a validated assay by capillary electrophoresis. (1995) (17)
- New taxane analogues from the needles of Taxus canadensis. (2001) (17)
- Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada – a time and motion study (2012) (17)
- Making Sense of Intratumor Genetic Heterogeneity: Altered Frequency of Androgen Receptor CAG Repeat Length Variants in Breast Cancer Tissues (2013) (17)
- AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. (2001) (16)
- In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933. (1993) (16)
- Elaeagnus angustifolia Plant Extract Inhibits Angiogenesis and Downgrades Cell Invasion of Human Oral Cancer Cells via Erk1/Erk2 Inactivation (2018) (16)
- Bridging structural biology and genetics by computational methods: An investigation into how the R774C mutation in the AR gene can result in complete androgen insensitivity syndrome (2003) (16)
- Ehd3, a regulator of vesicular trafficking, is silenced in gliomas and functions as a tumor suppressor by controlling cell cycle arrest and apoptosis. (2014) (16)
- Verapamil metabolites: potential P-glycoprotein-mediated multidrug resistance reversal agents. (2003) (15)
- Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma (2017) (15)
- Identification of performance indicators across a network of clinical cancer programs. (2016) (15)
- Emerging drug discovery approaches for selective targeting of "precursor" metastatic breast cancer cells: highlights and perspectives. (2011) (15)
- The importance of greater speed in drug development for advanced malignancies (2018) (15)
- A Phase I, Dose Escalation, Single Dose Trial of Oral Attenuated Salmonella typhimurium Containing Human IL-2 in Patients With Metastatic Gastrointestinal Cancers (2020) (15)
- Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes (2019) (15)
- Improving patient-care services at an oncology clinic using a flexible and adaptive scheduling procedure (2020) (14)
- How iMALDI can improve clinical diagnostics. (2018) (13)
- Connexin 43 pseudogene in breast cancer cells offers a novel therapeutic target (2009) (13)
- Identification of a novel steroid derivative, NSC12983, as a paclitaxel-like tubulin assembly promoter by 3-D virtual screening. (2001) (13)
- The relationship of self-rated health with functional status, toxicity and mortality: results of a prospective pilot study of older patients with newly-diagnosed cancer. (2013) (12)
- Glutathione and glutathione S‐transferases in clones of cultured rat liver epithelial cells that express varying activity of γ‐glutamyl transpeptidase (1989) (12)
- Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium (2022) (12)
- Interindividual variation in phase II detoxification enzymes in normal human colon mucosa. (1988) (12)
- Influence of phenobarbital induction on the enantioselective N-dechloroethylation of ifosfamide enantiomers in the rat. (1994) (12)
- Optimizing Treatment Sequencing of Chemotherapy for Patients with Rectal Cancer: the KIR Randomized Phase II Trial. (2020) (12)
- High-risk human papillomaviruses and Epstein–Barr virus in breast cancer in Lebanese women and their association with tumor grade: a molecular and tissue microarray study (2021) (12)
- Short and long-term barriers and facilitators of skin self-examination among individuals diagnosed with melanoma (2019) (11)
- CRAFT—A Proposed Framework for Decentralized Clinical Trials Participation in Canada (2021) (11)
- Æ-941, an inhibitor of angiogenesis: rationale for development in combination with induction chemotherapy/radiotherapy in patients with non-small-cell lung cancer (nsclc) (1999) (11)
- Increased glutathione S-transferase activity (GST) in drug treated human breast cancer cells (1985) (11)
- Transforming growth factor beta 1 promotes spontaneous transformation of cultured rat liver epithelial cells. (1994) (11)
- Genomic cloning and characterization of the rat glutathione S-transferase-A3-subunit gene. (1999) (11)
- Effect of proliferative state on glutathione S-transferase isoenzyme in cultured rat liver epithelial cells (1991) (10)
- Substantial Toxic Effect of Water-Pipe Smoking on the Early Stage of Embryonic Development (2018) (10)
- Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data (2019) (10)
- Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity (2004) (10)
- Sensitization effect of L-2-oxothiazolidine-4-carboxylate on tumor cells to melphalan and the role of 5-oxo-L-prolinase in glutathione modulation in tumor cells. (1998) (10)
- Redefining cancer: a new paradigm for better and faster treatment innovation. (2014) (10)
- Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer. (1997) (10)
- Changes in functional status in older newly-diagnosed cancer patients during cancer treatment: A six-month follow-up period. Results of a prospective pilot study (2011) (9)
- The nonapoptotic pathway mediating thymidine kinase/ganciclovir toxicity is reduced by signal from adenovirus type 5 early region 4. (2002) (9)
- Post-Transcriptional Regulation of Connexin43 in H-Ras-Transformed Cells (2013) (9)
- Cancer!? I Don't Have Time for That: Impact of a Psychosocial Intervention for Young Adults with Cancer. (2019) (9)
- The Role of Surrogate Markers in the Clinical Development of Antiretroviral Therapy: A Model for Early Evaluation of Targeted Cancer Drugs (2004) (9)
- A model for the interaction of paclitaxel with the Bcl-2 loop domain: a chemical approach to induce conformation-dependent phosphorylation. (2000) (9)
- Phase 1 study of CPX-1, a fixed ratio formulation of irinotecan (IRI) and floxuridine (FLOX), in patients with advanced solid tumors. (2006) (9)
- A 12‐gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5‐fluorouracil or FOLFIRI (2015) (8)
- Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cells. (1990) (8)
- Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer (2021) (8)
- Divergent mechanisms for loss of Ah-responsiveness in benzo[a]pyrene- and adriamycinR-resistant MCF-7 cells. (1999) (8)
- Drug resistance in cultured rat liver epithelial cells spontaneously and chemically transformed. (1992) (8)
- Phase II Study of Troxacitabine (BCH-4556) in Patients with Advanced Non-Small-Cell Lung Cancer (2005) (8)
- Achieving level patient flow in an outpatient oncology clinic (2018) (8)
- Novel use of the fluorescent dye 5‐(and‐6)‐chloromethyl SNARF‐1 acetate for the measurement of intracellular glutathione in leukemic cells and primary lymphocytes (2007) (8)
- Intravenous Total Parenteral Nutrition in Diabetic Renal Failure (1981) (8)
- Effect of DNA-repair-enzyme modulators on cytotoxicity ofl-phenylalanine mustard andcis-diamminedichloroplatinum (II) in mammary carcinoma cells resistant to alkylating drugs (2004) (8)
- Structure-based identification of novel human gamma-glutamylcysteine synthetase inhibitors. (2007) (8)
- Retrospective analysis of the effect of CAPOX and mFOLFOX6 dose intensity on survival in colorectal patients in the adjuvant setting. (2016) (7)
- PHARMACOKINETICS OF PAMIDRONATE DISODIUM IN CANCER PATIENTS AFTER A SINGLE INTRAVENOUS INFUSION OF 30‐, 60− OR 90‐mg DOSE OVER 4 OR 24 HOURS (1994) (7)
- The glutathione system in alkylator resistance. (2002) (7)
- Improving the therapeutic index when using Myocet™ in the treatment of metastatic breast cancer (2001) (7)
- Radiation resistance in a melphalan-resistant subline of a rat mammary carcinoma. (1994) (7)
- A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers. (2015) (7)
- Selenium. Preclinical studies of anticancer therapeutic potential. (1988) (6)
- Physician Recruitment of Patients to Non-Therapeutic Oncology Clinical Trials: Ethics Revisited (2013) (6)
- A Phase II Trial of Carboplatin (CBDCA) in Small‐Cell and Non‐Small‐Cell Lung Cancer with Correlation to In Vitro Analysis of Cytotoxicity (1990) (6)
- Biochemical characteristics of mouse mammary tissues, preneoplastic lesions and tumors. (1989) (6)
- Advances in the approach to novel drug clinical development for breast cancer (2014) (6)
- A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. (1996) (6)
- Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case Report (2019) (6)
- Induction of gamma-glutamyl transpeptidase activity by all-trans retinoic acid in cultured rat liver epithelial cells. (1988) (6)
- Why Tumor Genetic Heterogeneity May Require Rethinking Cancer Genesis and Treatment. (2020) (6)
- Phase I study of ECO-4601, a novel Ras pathway inhibitor (2007) (5)
- NCIC CTG IND.122: a phase I/II pharmacokinetics (PK) and pharmacodynamic (PD) study of zd1839 (iressa ‘TM’). Final phase I results and preliminary phase II results of ZD1839 (750 mg/day) in patients (pts) with colorectal cancer (2001) (5)
- SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. (2003) (5)
- Copresence of High-Risk Human Papillomaviruses and Epstein–Barr Virus in Colorectal Cancer: A Tissue Microarray and Molecular Study from Lebanon (2021) (5)
- Coronary bypass surgery in juvenile onset diabetes. (1983) (5)
- Effect of proliferative state on glutathione S-transferase isoenzyme expression in cultured rat liver epithelial cells. (1991) (5)
- Multiplexed real-time polymerase chain reaction cell-free DNA assay as a potential method to monitor stage IV colorectal cancer. (2019) (5)
- Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion (2004) (5)
- Plasma Exchange in Late Gestosis (1981) (5)
- New frontiers in therapeutic resistance in cancer (2012) (5)
- Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors (2021) (5)
- Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies (2005) (5)
- Using two peptide isotopologues as internal standards for the streamlined quantification of low-abundance proteins by immuno-MRM and immuno-MALDI. (2020) (5)
- The Peter Brojde lung cancer centre: a model of integrative practice. (2012) (5)
- Treatment sequencing in MPC, insights from a 3˚ care center. (2019) (4)
- The McGill University Department of Oncology: structure depicts the shape of evolving knowledge (2008) (4)
- Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker Controversy. (2021) (4)
- A novel parasite-derived suicide gene for cancer gene therapy with specificity for lung cancer cells. (2001) (4)
- A Dose Escalation Phase II Study using Intensity Modulated Radiation Therapy (IMRT) and Concurrent Chemotherapy for Patients with Advanced Rectal Cancer and Magnetic Resonant Imaging (MRI) Defined Positive Circumferential Radial Margins (CRM (2011) (4)
- Ratiometric dosing of irinotecan (IRI) and floxuridine (FLOX) in a phase I trial: A new approach for enhancing the activity of combination chemotherapy (2007) (4)
- HUMAN COLON CARCINOMA HAS THE SAME BIOCHEMICAL PHENOTYPE AS RESISTANT CARCINOGEN -INDUCED PRE-NEOPLASTIC NODULES AND AS HUMAN BREAST CANCER CELLS WITH MULTIDRUG RESISTANCE (1987) (3)
- "Ifosfamide: should the honeymoon be over?": a two-dimensional question for a three-dimensional problem. (1995) (3)
- Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival (2021) (3)
- Perioperative chemotherapy with bevacizumab (BV) for liver metastases (LM) in colorectal cancer (CRC): McGill University pilot study. (2009) (3)
- L04.04 * Winther: a study to select rational therapeutics based on the analysis of tumor and matched normal tissue biopsies in subjects with advanced malignancies (2013) (3)
- Perioperative bevacizumab (Bev) containing chemotherapy for colorectal liver metastases (2008) (3)
- A pilot study on frailty, health and functioning in older newly-diagnosed cancer patients, what have we learned? (2011) (3)
- A Phase I study of ‘Tomudex’ and gemcitabine in advanced cancer (1999) (3)
- A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer (2004) (3)
- Reversible low-dose bleomycin lung disease. (1980) (3)
- Folfirinox (FFX) versus gemcitabine with nab‐paclitaxel (GNP) in the first line treatment (1LTx) of metastatic pancreatic cancer (mPC): A tertiary center experience. (2018) (3)
- Usefulness of frailty markers in the assessment of the health and functional status in older cancer patient referred for chemotherapy (2007) (2)
- Does the Compliance to Adjuvant Chemotherapy Depend on Neoadjuvant Radiation Therapy Modality (2012) (2)
- Abstract CT098: Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies (2017) (2)
- Safety of bevacizumab when given perioperatively for colorectal cancer with liver metastases: McGill University pilot study. (2016) (2)
- A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens (2022) (2)
- A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer. (2020) (2)
- Developing a model of a patient-group pathway to accessing cancer clinical trials in Canada. (2018) (2)
- Site-Specific Variation in Radiomic Features of Head and Neck Squamous Cell Carcinoma and Its Impact on Machine Learning Models (2021) (2)
- Orally Administered Multiple Dose Saltikva (Salmonella-IL2) in Conjunction with Folfirinox in a Patient with Stage IV Pancreatic Cancer: A Case Report (2020) (2)
- New Insights into the Pharmacokinetics and Metabolism of (R,S)-Ifosfamide in Cancer Patients Using a Population Pharmacokinetic-Metabolism Model (2000) (2)
- Growth Factor Receptor Signaling, DNA Damage Response, and Cancer Cell Susceptibility to Chemotherapy and Relapses (2013) (2)
- An open label safety and efficacy phase 2a study of the N-cadherin (N-cad) antagonist ADH-1 in subjects with N-cadherin expressing solid tumors (2016) (2)
- A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012. (2013) (2)
- Identification of the Yc1 glutathione S‐Transferase mRNA as the overexpressed species in a nitrogen mustard–resistant rat mammary carcinoma cell line (1998) (2)
- Abstract CT083: A Phase I/II study of aurora kinase A inhibitor, LY3295668 erbumine (AK-01): Safety as monotherapy in patients with locally advanced or metastatic solid tumors (2019) (2)
- Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer (2021) (2)
- Cardiac safety and efficacy of TLC D99 (D99) and trastuzumab in patients with advanced breast cancer (2001) (2)
- Five-yeAr experience oF McGill University's Adolescent And yoUnG AdUlt oncoloGy proGrAM The challenge of serving a unique population (2009) (2)
- A phase I study of BAY 38-3441 given as a short infusion daily for five days every 3 weeks. a National Cancer Institute of Canada Clinical Trials Group Study (2001) (2)
- Neoadjuvant chemotherapy with cytosine arabinoside by continuous infusion and cisplatin for resectable squamous cell carcinoma of the esophagus (1992) (2)
- Cytotoxicity and extent of protein associated dna strand breaks by etoposide vp 16 213 and teniposide vm 26 and their quinone metabolites in a human breast cancer cell line (1986) (2)
- Systematic Optimization of the iMALDI Workflow for the Robust and Straightforward Quantification of Signaling Proteins in Cancer Cells (2020) (1)
- Abstract 3389: Determining optimal conditions for collection and processing of metastatic liver biopsies collected for a multicenter, prospective study to identify biomarkers of clinical resistance to first-line therapy in metastatic colorectal cancer (2012) (1)
- Effect of cell‐phone radiofrequency on angiogenesis and cell invasion in human head and neck cancer cells (2018) (1)
- Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition (2020) (1)
- Case-Control Study of Colorectal Cancer and Fecal Mutagenicity 1 (2006) (1)
- Implications of rapid uniform density changes on hepatic computed tomography. (1983) (1)
- The Rossy Cancer Network : A philanthropy-driven quality program (2013) (1)
- Cullin-3 is a potential novel target for breast cancer chemoprevention and treatment. (2006) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies. (2017) (1)
- Pancreatic adenocarcinoma in adolescent and young adults (18-44): Characteristics and clinical outcomes from Canada and France. (2015) (1)
- Gemcitabine plus nab-paclitaxel use in metastatic pancreatic cancer: A study of 40 patients. (2017) (1)
- Access Denied? The Unintended Consequences of Pending Drug Pricing Rules (2022) (1)
- A census of cancer physicians in the province of Quebec: clinical experience with elderly patients (2008) (1)
- Therapeutic management of metastatic breast cancer across Europe: European observatory and survey (EOS). (2011) (1)
- Impact of dose intensity of XELOX and MFOLFOX6 on survival of metastatic colorectal cancer patients: A retrospective analysis at the Jewish General Hospital between 2006 and 2013. (2014) (1)
- 267 IMPACT OF TIMING OF CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH OPERABLE RECTAL CANCER: PRELIMINARY RESULTS FROM A RANDOMIZED PHASE II STUDY (2012) (1)
- The Role of Selenium Compounds in Cancer Therapy (1986) (1)
- A study of preoperative FOLFIRINOX in potentially curable pancreatic cancer. (2020) (1)
- Evidence for genomic duplication of the glutathione transferase A3 gene in genus Rattus. (2000) (1)
- Neurocognitive function and psychological distress in young adults (YA) with cancer. (2016) (1)
- Abstract 579: Immune features and neoantigen recognition in mismatch repair-proficient colorectal cancer liver metastases (2019) (1)
- A phase I/II study of vaccination with autologous dendritic cells (DCs) transfected with autologous amplified tumor-derived mRNA in patients with stage IV renal cell carcinoma (RCC) (2005) (1)
- Bevacizumab (Bev)-based therapy for patients (pts) with colorectal cancer (CRC): McGill University and Segal Cancer Centre experience. (2011) (1)
- Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung (2022) (1)
- BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER - THE MCGILL EXPERIENCE (2010) (1)
- 755PPrognostic value of neutrophil-lymphocyte ratio in first line treatment for metastatic pancreatic adenocarcinoma (2017) (1)
- Q-CROC-03: A prospective biopsy driven clinical trial to study the mechanisms of resistance to chemotherapy in triple-negative breast cancer patients. (2012) (1)
- Clinical Evaluation of Vitamin C and other Micronutrients in the Treatment of Cancer (1)
- Recruiting older newly-diagnosed cancer patients for an observational ongoing prospective cohort study: lessons learned (2008) (1)
- A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110α in cell lines and tumor tissues. (2021) (1)
- Design and syntheses of putative bioactive taxanes. (2002) (1)
- Neurocognitive functions and psychological distress in young adults with cancer (YAC): A prospective, longitudinal study. (2017) (1)
- Surrogate Endpoints in Colorectal Cancer (2005) (1)
- 338. Comparing characteristics and survival outcomes of adolescent and young adults to mature patients with colorectal cancer (2016) (0)
- Outcomes of first-line FOLFIRINOX (FFX) versus gemcitabine and nab-paclitaxel (GN) in patients with advanced pancreatic cancer: Multi-Institutional Canadian sites experience (2019) (0)
- 2054 Clinical outcomes of adolescent and young adult patients (AYAp) vs mature adult patients (MATp) with colorectal cancer (CRC), a multi-institutional retrospective review (2015) (0)
- IFOSFAMIDE : SHOULD THE HONEYMOON BE OVER ? : A TWO-DIMENSIONAL QUESTIONFOR A THREE-DIMENSIONAL PROBLEM. AUTHORS' REPLY (1995) (0)
- Abstract LB-177: Quantification of cell signaling proteins by immuno-MALDI (2018) (0)
- 743P A phase Ib dose escalation study of CD137 mAb agonist OC-001 as monotherapy in patients with advanced or metastatic cancer (2022) (0)
- Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies? Ursini-Siegel* (2013) (0)
- Immuno-multiple reaction monitoring (iMRM) for quantitation of PD-L1 and PD-1-signaling proteins in non-small cell lung carcinoma (NSCLC). (2022) (0)
- Front Cover: Systematic Optimization of the iMALDI Workflow for the Robust and Straightforward Quantification of Signaling Proteins in Cancer Cells (2020) (0)
- Treatment patterns and progression-free survival (PFS) in first-line metastatic colorectal (mCRC) patients (pts) on an oxaliplatin-based chemotherapy (OX-t): A Canadian retrospective chart review. (2014) (0)
- P3.07 Building the Organization Framework for Biopsy-Driven Translational Research: The Quebec Clinical Research Organization in Cancer (Q-Croc) Experience (2012) (0)
- Targeted Treatment With Anti-EGFR Antibodies and Radiation Therapy for Patients With Squamous Cell Carcinoma of the Anal Canal: Rationale for a New Treatment Strategy (2012) (0)
- Abstract CT035: Addition of Salmonella-IL2 to FOLFIRINOX for metastatic stage 4 pancreatic cancer nearly doubles median survival (2023) (0)
- Induction of Ephs/Ephrins-Mediated Tumor Cells-Endothelial Cells Repulsion as an Anti-Cancer Therapeutic Approach (2005) (0)
- Corrigendum to “Design and Syntheses of Putative Bioactive Taxanes” [Bioorg. Med. Chem. (2002) 2387–2395] (2003) (0)
- Author Correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial (2022) (0)
- Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009. (2013) (0)
- An update on the overall epidemiology, clinical characteristics, and outcomes from the COVID-19 and Cancer Consortium (CCC19). (2022) (0)
- Immuno-MALDI-MS for Accurate Quantitation of Targeted Peptides from Volume-Restricted Samples. (2022) (0)
- Phase II trial of sorafenib (S) and vinorelbine (V) in metastatic breast cancer (mBC) with pharmacokinetics (PK) analysis. (2012) (0)
- OC-0279: A randomized phase II study testing for optimal strategy for patients with high risks rectal cancer (2018) (0)
- P3.02 Challenges in The Implementation of a Translational Research Biopsy-Driven Trial to Study Drug Resistance in Triple Negative Breast Cancer Patients (2012) (0)
- [Delivery in hypoxic tumor regions of a chemotherapeutic agent encapsulated in nanoliposomes carried by magnetoaerotactic bacteria]. (2018) (0)
- 2149 Impact of dose intensity in CAPOX and mFOLFOX6 in the treatment of metastatic colorectal cancer (2015) (0)
- Treatment Access, Health Economics, and the Wave of a Magic Wand (2022) (0)
- Case-Control Study of Colorectal Cancer and Fecapentaene Excretion1 (2006) (0)
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (0)
- Transforming Growth Spontaneous Transformation of Cultured Rat Liver Epithelial Cells1 (2006) (0)
- Pyk 2 and its phosphorylated form pY 881 are novel prognostic markers for non-small cell lung cancer progression and patients ' survival (2015) (0)
- Cancer-related cognitive dysfunction (CRCD) and psychosocial development in young adult cancer survivors. (2015) (0)
- Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition (2020) (0)
- Medication problems in older newly-diagnosed cancer patients in Canada, how often does it occur? (2008) (0)
- Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits (2017) (0)
- A novel way of assessing health and vulnerability in older newly diagnosed cancer patients: preliminary results of an ongoing prospective pilot study. (2007) (0)
- Pancreatic neuroendocrine tumors (pNET) in adolescent and young adult (AYA) population: A multi-institutional study of characteristics and outcomes. (2015) (0)
- 147TiP Exactis-01 - Clinical utility of returning liquid biopsy NGS results in NSCL cancer patients: A Canadian trial through the Exactis Network (2022) (0)
- Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent (2007) (0)
- High-risk human papillomaviruses and Epstein–Barr virus in breast cancer in Lebanese women and their association with tumor grade: a molecular and tissue microarray study (2021) (0)
- Development of Novel Sodium Fluoride-PET Response Criteria for Solid tumors ( NAFCIST ) in Osteosarcoma : From RECIST to NAFCIST (2017) (0)
- A phase I and pharmacokinetic (PK) study of vinorelbine liposomes injection in patients with advanced solid tumors, non-Hodgkin’s lymphoma, and Hodgkin’s disease (2007) (0)
- False-negative HER2 tests with appropriate positive controls. (2010) (0)
- Abstract 2795: Integrating multiomics discovery approaches to identify biomarkers of therapeutic resistance in metastatic colorectal cancer through analyses of multiple sequential tumor and liquid biopsies; Qcroc01: NCT00984048 (2017) (0)
- 396PUSE OF LIPOSOMAL DOXORUBICIN FOR METASTATIC BREAST CANCER MANAGEMENT ACROSS EUROPE: RESULTS OF EOS (EUROPEAN OBSERVATORY & SURVEY). (2014) (0)
- Short and Long-term Barriers and Facilitators of SSE Among Individuals with Melanoma (2019) (0)
- Abstract LB-231: Genomic profiling in serial metastatic colorectal tumors identifies copy number alterations and spatio temporal intra-patient heterogeneity profiles associated with clinical response. Q-CROC-01: NCT00984048 (2018) (0)
- A phase IV study using multi-omics to identify mechanisms of response and resistance to crizotinib in ALK+ advanced non-small cell lung cancer (NSCLC) patients with distinct progression free survival outcomes. (2017) (0)
- Role of Free-Radical Metabolic Pathways (2005) (0)
- P.32 Clinical experience of physicians involved in cancer treatment of older cancer patients: a qualitative interview study (2007) (0)
- Transcriptional repression of TFIIH subunits XPB/ERCC3 and XPD/ERCC2 by hepatitis B virus X protein (1997) (0)
- Use of denaturing high performance liquid chromatography (dHPLC) for detection of EGFR mutations in patients with NSCLC. (2006) (0)
- Abstracts from the 33rd Annual Scientific Meeting of the Canadian Geriatrics Society Toronto, April 2013 (2013) (0)
- Technology & tools development (2012) (0)
- Abstract P1-19-05: Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer (2020) (0)
- Design and Synthesis of Analogues of Vitamine E: Antiproliferative Activity Against Human Breast Adenocarcinoma Cells. (1999) (0)
- Biopsies: next-generation biospecimens for tailoring therapy (vol 10, pg 437, 2013) (2013) (0)
- Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies (2022) (0)
- Abstract 3888: Molecular profiling of sequential biopsies in patients with metastatic colorectal cancer identifies genomic alterations that evolve during first-line therapy and could have therapeutic implications: A prospective study to identify molecular mechanisms of clinical resistance (QCROC-01: (2015) (0)
- Abstract 4325: A Phase II exploratory study to identify biomarkers prognostic of clinical response to regorafenib in patients with metastatic colorectal cancer who have failed first-line therapy (2020) (0)
- Abstract S12-01: High mortality among hospital-acquired COVID-19 infection in patients with cancer: An observational cohort study from Quebec and British Columbia (2020) (0)
- P-306A phase II biopsy-driven study to identify biomarkers predictive of clinical response to second-line regorafenib in patients with metastatic colorectal cancer (2015) (0)
- Molecular predictors of long-term response to crizotinib in ALK+ advanced non-small cell lung cancer (NSCLC) patients. (2018) (0)
- Oral and Poster Papers Submitted for Presentation at the 5th Congress of the EUGMS “Geriatric Medicine in a Time of Generational Shift September 3–6, 2008 Copenhagen, Denmark (2008) (0)
- Lung Cancer Pre-Diagnostic Pathways from First Presentation to Specialist Referral (2021) (0)
- Abstract B21: Protein quantitation assays for Akt, PI3K p110α, and PTEN to assess PI3K pathway activity in tumor tissue (2020) (0)
- Abstract 5534: Building the organization framework for biopsy-driven translational research: The Quebec Clinical Research Organization in Cancer (Q-CROC) experience (2012) (0)
- Abstract 2706: Phase 2 study with pharmacokinetics (PK) analysis of sorafenib and vinorelbine in metastatic breast cancer (2012) (0)
- 32 A census of cancer physicians in the province of Quebec: clinical experience with elderly patients (2006) (0)
- tor Regulation after Transfection into a Cell Line Deficient in the cAMP-Dependent (1989) (0)
- Abstract 2149: Use of PDXs and patient-derived cell lines to uncover unconventional drug therapies and combinations for the treatment of drug-resistant cancers (2018) (0)
- Introduction: Breast Cancer Progression and Metastasis: Experimental Studies and Clinical Translation (2001) (0)
- A multi-institutional randomized phase II study on the timing of oxaliplatin plus 5-fluorouracil (FOLFOX) for patients (pts) with operable stage III rectal cancer: The KIR study. (2018) (0)
- Abstract P4-10-20: Protein quantitation assays for AKT and PTEN to better understand sensitivity and resistance of breast cancer patients to treatment with AKT inhibitor capivasertib (2020) (0)
- Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene mutations detected by denaturing high-performance liquid chromatography (dHPLC) in non-small cell lung cancer (NSCLC) (2007) (0)
- Bioinformatic / MS proteomic approach to identify a panel associated with the response to therapy in drug-resistant ovarian cancer tissue (2017) (0)
- Herceptin® treatments in hospital and at CLSCs for breast cancer patients in Quebec: comparative analysis of costs and care trajectories.Herceptin® treatments in hospital and at CLSCs for breast cancer patients in Quebec: comparative analysis of costs and care trajectories. (2023) (0)
- A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology (2023) (0)
- Biopsy-driven study to identify biomarkers predictive of clinical response to second-line regorafenib in patients with metastatic colorectal cancer. (2014) (0)
- A network approach to developing immuno-oncology combinations in Canada. (2019) (0)
- More is not better. a time-dependent analysis of mortality in association with multiple treatments in the management of metastatic colorectal cancer. (2016) (0)
- Differential Uptake Volume Histograms as a Predictor of Response in Rectal Adenocarcinoma Patients Treated with Preoperative Endorectal Brachytherapy (2017) (0)
- Characterizations of DNA copy number variations and spatio-temporal intra tumor heterogeneity in liver metastasis from colorectal cancer patients. (2018) (0)
- Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer (2021) (0)
- Abstract 820: Somatic mutations to identify tumors for highly selective chemosensitization by Nrf2 depletion (2012) (0)
- MC13-0077 Array CGH analysis of paired metastatic biopsies obtained pre-treatment and at resistance to FOLFOX-bevacizumab in metastatic CRC patients (2013) (0)
- In Vivo and in Vitro Mechanisms of Drug Resistance in a Rat Mammary Carcinoma Model 1 (2006) (0)
- Barriers and facilitators of skin self-examination among patients diagnosed with melanoma (2019) (0)
- P19 A novel way of assessing health and vulnerability in older newly-diagnosed cancer patients: results of a pilot study (2009) (0)
- P-037Advanced Pancreatic Cancer Patients' Characteristics, Treatment and Outcome Based on Three Age Groups: ≤ 39, 39-74 and ≥ 75, a Report from Single Cancer Institution (2015) (0)
- Ultrasound-Guided Percutaneous Needle Biopsy of Colorectal Liver Metastases in Personalized Medicine : Evaluation of Standard Operating Procedures to Optimize Biospecimen Quality for Genomics Analysis . A Part of the Q-CROC-01 Project (2018) (0)
- P2.01-23 Baseline Plasma Biomarkers Predict Long-Term Responses to ALK-TKIs in ALK+ Advanced Non-Small Cell Lung Cancer (NSCLC) (2018) (0)
- Are XELOX and FOLFOX equivalent in colorectal cancer? Dose intensity, toxicity, and treatment duration in clinical practice. (2013) (0)
- Abstract A07: Sequential ctDNA analysis detected preclinical relapse in patients with metastatic colorectal cancer from the Exactis trial (NCT00984048) (2020) (0)
- A novel way of assessing health and vulnerability in older newly diagnosed cancer patients: An ongoing prospective pilot study (2008) (0)
- Phase II : Face-to-Face Discussion and Iterative Ratings (2016) (0)
- Brief Report A Novel Parasite-Derived Suicide Gene for Cancer Gene Therapy with Specificity for Lung Cancer Cells (2001) (0)
- Factors influencing human tumor radioresistance (1994) (0)
- Efficacy and Toxicity of Ifosfamide Stereoisomers in an in Vivo Rat Mammary Carcinoma Model 1 (2006) (0)
- Liquid chromatography coupled to multiple reaction monitoring (LC-MRM) for quantification of PD-L1 and PD1-signaling proteins in non-small cell lung carcinoma (NSCLC). (2020) (0)
- 2354 Is pancreatic adenocarcinoma more aggressive in adolescents and young adults? A multi-institute retrospective study (2015) (0)
- A phase I study of escalating interferon alpha-2a combined with 5-fluorouracil and leucovorin in patients with gastrointestinal malignancies. (1993) (0)
- Bridging structural biology and genetics by computational methods: An investigation into how the R774C mutation in the AR gene can result in complete androgen insensitivity syndrome (2004) (0)
- Reply to: Concerns about estimating relative risk of death associated with convalescent plasma for COVID-19 (2022) (0)
- PCN252 TIME-TO-TREATMENT INITIATION (TTI) IN COMMUNITY INFUSION CLINICS: DECREASING WAIT TIMES FOR CANADIAN ONCOLOGY PATIENTS (2020) (0)
- Impact of dose intensity of capox and mFOLFOX6 on survival of stage III colorectal cancer patients: A retrospective analysis at two Canadian institutions between 2006-2013. (2015) (0)
- 2359 Optimal therapeutic sequences in the treatment of metastatic pancreatic cancer - a retrospective analysis from two Canadian and French tertiary cancer centres (2015) (0)
- Short and long-term barriers and facilitators of skin self-examination among individuals diagnosed with melanoma (2020) (0)
- Biopsy-driven study to identify biomarkers of drug resistance in patients with triple-negative breast cancer. (2012) (0)
- PO-0703: Does neoadjuvant chemotherapy improve the pathologic complete remission rate for rectal cancer patients? (2014) (0)
- Transcriptomics in Tumor and Normal Tissues and Precision Oncology Algorithms Identify Early-Stage NSCLC Patients with High Risk of Post-Surgery Recurrence Who May Benefit from Adjuvant Therapies (2021) (0)
- Clinical outcomes of adolescent and young adults (AYA) with colorectal cancer (CRC), a multi-institutional retrospective review (MIRR). (2015) (0)
- Abstract B24: De novo and acquired resistance to first-line standard therapy in colorectal cancer: from cell lines to metastatic tumors (2012) (0)
- PD-0035THE CANADIAN COLORECTAL CANCER CONSORTIUM: THE FIRST LARGE-SCALE MOLECULAR BASED APPROACH TO TRANSLATIONAL CANCER CARE IN CANADA (2013) (0)
- Co-presence of human papillomaviruses and Epstein–Barr virus is linked with advanced tumor stage: a tissue microarray study in head and neck cancer patients (2020) (0)
- First-line drug selection versus sequential treatment in advanced pancreatic cancer: Does it really matter? Multi-institutional Canadian perspective. (2020) (0)
- Abstract 4835: Gonosome-linked expression of PPP2R3B in cutaneous melanoma correlates with distant metastasis free survival (2011) (0)
- Abstract CT019: Population pharmacokinetics of an aurora kinase A inhibitor, LY3295668 erbumine (AK-01), in patients with locally advanced or metastatic solid tumors (2019) (0)
- 1558PA patient-centered approach to the re-development of supportive care services for oncology adolescent and young adult (AYA) patients (pt(s)) across McGill University hospitals (Rossy Cancer Network-RCN) (2017) (0)
- Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy. (2019) (0)
- Abstract 6494: Personalize My Treatment (PMT): A pan-Canadian initiative integrating precision oncology across Canada - PMT-001 pilot project (2020) (0)
- Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma (2023) (0)
- PAPER OF THE MONTHOCTObER 2013 (2013) (0)
- Abstract 5575: A multiplexed RE-qPCR cell-free DNA assay to assess response and resistance to cancer therapy (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Gerald Batist?
Gerald Batist is affiliated with the following schools:
